Cure8 research brief
People with IBD or their clinicians may worry that systemic antifungal treatment could trigger flares.
This study’s abstract reports no increased relapse risk linked to oral fluconazole and similar chances of remission for those with active disease, which could be reassuring if antifungal treatment is needed for standard indications.
Adult patients with IBD (Crohn’s disease or ulcerative colitis), IBD clinicians, and researchers interested in medication interactions and infection management in IBD.
This retrospective matched study reviewed IBD patients who received oral fluconazole between 2012–2023 and compared them 1:2 with matched controls who did not receive fluconazole.
The primary finding reported in the abstract is that fluconazole use was not associated with an increased rate of relapse among patients in remission, and among patients with active disease at baseline there was no difference in time-to-remission. The most common indication for fluconazole in the cohort was vaginal candidiasis.
The study included 77 fluconazole-treated patients and 152 matched controls. The authors used Cox regression to compare time-to-relapse (for those in remission at baseline) and time-to-remission (for those with active disease).
An exploratory subgroup analysis suggested longer fluconazole courses (>2 weeks) were associated with faster remission compared with very short courses (1–3 days), but this is presented as exploratory. This brief is grounded in the source-provided abstract (structured content depth: abstract).
It summarizes what the abstract reports without implying results beyond the published abstract or providing clinical recommendations.
This is a retrospective, single-institution matched analysis reported in an abstract. The subgroup finding about longer courses is exploratory. The abstract alone does not provide full methods, safety details, or adjustments for all potential confounders; consult the full paper and clinical guidance before changing treatment decisions.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This Taiwanese multicenter real-world study reports high 52-week clinical response and remission rates, sustained one-year drug persistence, and meaningful fistula healing with ustekinumab in patients with Crohn’s...
People with Crohn’s disease on ustekinumab may be more likely to need intensified dosing if they previously tried biologics or immunomodulators or have had disease longer; this could affect monitoring and planning. For...
The study addresses a practical question for people with IBD: whether sequencing anti-TNF therapy after a biologic from a different class affects how well the anti-TNF works. Shorter durability — especially in ulcerative...
